IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech, Inc. (IOBT)
Company Research
Source: GlobeNewswire
NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California. “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “We now clearly see that used together, IO102-IO103 create an environment in and around the tumor that allow for enhanced anti-tumor activity, at a much greater level than either could do on its own. With this additional data, we further understand the mechanistic rationale for the clinical effect observed in the Phase 1/2 study of IO102-IO103 that we hope to confirm in our ongoing Phase 3 pivota
Show less
Read more
Impact Snapshot
Event Time:
IOBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOBT alerts
High impacting IO Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
IOBT
News
- IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness [Yahoo! Finance]Yahoo! Finance
- IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessGlobeNewswire
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerGlobeNewswire
IOBT
Earnings
- 11/13/23 - Beat
IOBT
Analyst Actions
- 3/6/24 - HC Wainwright
IOBT
Sec Filings
- 4/26/24 - Form 8-K
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- IOBT's page on the SEC website